Cerevel Therapeutics Announces the Appointment of Seasoned Finance Executive, Gabrielle Sulzberger, to its Board of Directors
BOSTON--(BUSINESS WIRE)--Nov 4, 2019--
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Gabrielle Sulzberger to serve as an independent member of its Board of Directors. Ms. Sulzberger is the former chairperson of the board of Whole Foods and an accomplished financial services professional with over 30 years of experience in both private equity and as a chief financial officer across a broad range of industries, including consumer goods, retail, financial services and healthcare. She also possesses extensive corporate governance expertise, having served on the boards of several publicly-traded and privately-held companies, with particular expertise in mergers and acquisitions, risk assessment, as well as engagement with shareholder activists.
“Gabrielle is a proven leader with a unique background and skillset, which we feel will complement and strengthen our existing team,” said Tony Coles, M.D., chief executive officer and chairperson of Cerevel Therapeutics. “We’re confident that the diverse range of business circumstances she’s experienced throughout her career will offer an invaluable perspective, and we’ll look to her knowledge to help us navigate through complex situations, corporate milestones, and different phases of growth and expansion.”
“It is such an exciting and unprecedented period of innovation in the biopharmaceutical industry,” said Ms. Sulzberger. “The progress this team is making to develop new treatments for some of the most under-served and complex diseases is what attracted me to the opportunity, and I look forward to helping the organization realize its full potential to become a premier neuroscience company.”
About Gabrielle Sulzberger
Ms. Sulzberger currently serves as general partner of Rustic Canyon/Fontis Partners, a position she has held since 2007. Prior to joining RC/Fontis, Ms. Sulzberger served as chief financial officer of several public and private companies, including Gluecode Software, a venture-backed open source software company which was sold to IBM, and Crown Services, a California-based consolidation of commercial contractors.
Until August of 2017, Ms. Sulzberger served as chairperson of the board of Whole Foods and previously spent 13 years as chairperson of Whole Foods’ audit committee. She currently serves on the boards of MasterCard, Brixmor Property Group, where she chairs the governance committee, and two private-equity backed companies: Acorns and True Food Kitchen, where she also serves as chairperson. Ms. Sulzberger has also served on four other public company boards: Teva Pharmaceuticals, Stage Stores, IndyMac Bank, and Bright Horizons, as well as numerous private company boards.
Ms. Sulzberger is a Trustee of the Ford Foundation. She also serves on the boards of the Women Corporate Directors Foundation, the National Association of Corporate Director’s Audit Advisory Council, Trinity Church Wall Street and is a Henry Crown Fellow of the Aspen Institute. In 2014 she was named a “Top 100 Director” by the National Association of Corporate Directors.
Ms. Sulzberger earned her B.A. from the Woodrow Wilson School of Princeton University. She received her M.B.A. from Harvard Business School and J.D. from Harvard Law School and is a member of the Massachusetts Bar.
About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia and substance use disorders. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit www.cerevel.com.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our potential to become a premier neuroscience company and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005109/en/
CONTACT: Rachel Eides
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Cerevel Therapeutics
Copyright Business Wire 2019.
PUB: 11/04/2019 08:00 AM/DISC: 11/04/2019 08:01 AM